Literature DB >> 24807464

Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study.

Petra G van Peet1, Anton J M de Craen, Jacobijn Gussekloo, Wouter de Ruijter.   

Abstract

In the aging society, it is important to identify very old persons at high risk of functional decline, cardiovascular disease and mortality. However, traditional risk markers lose their predictive value with age. We investigated whether plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels predict change in functional status, cardiovascular morbidity and mortality in very old age. Here we present an observational prospective cohort study (Leiden 85-plus Study, 1997-2004) in a population-based sample of 560 individuals aged 85 years with a 5-year complete follow-up for functional status, cardiovascular morbidity and cause-specific mortality. Median NT-proBNP for men was 351 pg/ml (cutoff values for low-medium tertiles 201 pg/ml and medium-high tertiles 649 pg/ml) and, for women, 297 pg/ml (cutoffs 204 and 519 pg/ml, respectively). During the 5-year follow-up, participants with high NT-proBNP had an accelerated cognitive decline and increase of activities of daily living (ADL) disability over time (all at p < 0.01) and an increased risk of incident heart failure [hazard ratio (HR) 3.3 (95 % confidence interval (CI) 1.8-6.1)], atrial fibrillation [HR 4.1 (2.0-8.7)], myocardial infarction [HR 2.1 (1.2-3.7)], stroke [HR 3.4 (1.9-6.3)], cardiovascular mortality [HR 5.5 (3.1-10)], non-cardiovascular mortality [HR 2.0 (1.4-3.0)] and all-cause mortality [HR 2.9 (2.1-4.0)], independent of other known risk markers. All results remained similar after exclusion of participants with heart failure at baseline. In very old age, high-NT-proBNP levels predict accelerated cognitive and functional decline, as well as cardiovascular morbidity and mortality. Results suggest that NT-proBNP can help clinicians to identify very old people at high risk of functional impairment and incident cardiovascular morbidity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24807464      PMCID: PMC4082596          DOI: 10.1007/s11357-014-9660-1

Source DB:  PubMed          Journal:  Age (Dordr)        ISSN: 0161-9152


  56 in total

Review 1.  The mini-mental state examination: a comprehensive review.

Authors:  T N Tombaugh; N J McIntyre
Journal:  J Am Geriatr Soc       Date:  1992-09       Impact factor: 5.562

2.  Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons.

Authors:  Ryuji Ueda; Masatoshi Yokouchi; Takaomi Suzuki; Eiichi Otomo; Takashi Katagiri
Journal:  Am J Med       Date:  2003-03       Impact factor: 4.965

3.  Correlation between cognitive impairment and left ventricular diastolic dysfunction in patients with cardiovascular diseases.

Authors:  Michihiro Suwa; Takahide Ito
Journal:  Int J Cardiol       Date:  2008-08-06       Impact factor: 4.164

4.  Accuracy of the 15-item geriatric depression scale (GDS-15) in a community sample of the oldest old.

Authors:  Anton J M de Craen; T J Heeren; Jacobijn Gussekloo
Journal:  Int J Geriatr Psychiatry       Date:  2003-01       Impact factor: 3.485

5.  Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians.

Authors:  Bert Vaes; Wouter de Ruijter; Jan Degryse; Rudi G J Westendorp; Jacobijn Gussekloo
Journal:  J Am Geriatr Soc       Date:  2009-05       Impact factor: 5.562

6.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2004-02-12       Impact factor: 91.245

7.  Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population.

Authors:  B A Groenning; I Raymond; P R Hildebrandt; J C Nilsson; M Baumann; F Pedersen
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

Review 8.  A note on competing risks in survival data analysis.

Authors:  J M Satagopan; L Ben-Porat; M Berwick; M Robson; D Kutler; A D Auerbach
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

9.  NT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus Study.

Authors:  Petra G van Peet; Yvonne M Drewes; Anton J M de Craen; Jacobijn Gussekloo; Wouter de Ruijter
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  C-reactive protein and B-type natriuretic peptide yield either a non-significant or a modest incremental value to traditional risk factors in predicting long-term overall mortality in older adults.

Authors:  Alline M Beleigoli; Eric Boersma; Maria de Fátima H Diniz; Pedro G Vidigal; Maria Fernanda Lima-Costa; Antonio L Ribeiro
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more
  10 in total

1.  Association of BNP with Frailty in Elderly Population: Rugao Longevity and Ageing Study.

Authors:  S Yao; J Guo; G Shi; Y Zhu; Y Wang; X Chu; X Jiang; L Jin; Z Wang; X Wang
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Level and Change in N-Terminal Pro-B-Type Natriuretic Peptide and Kidney Function and Survival to Age 90.

Authors:  Astrid D Häberle; Mary L Biggs; Mary Cushman; Bruce M Psaty; Anne B Newman; Michael G Shlipak; John Gottdiener; Chenkai Wu; Julius M Gardin; Nisha Bansal; Michelle C Odden
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-02-25       Impact factor: 6.053

3.  The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.

Authors:  Qiwei Zhu; Wenkai Xiao; Yongyi Bai; Ping Ye; Leiming Luo; Peng Gao; Hongmei Wu; Jie Bai
Journal:  Clin Interv Aging       Date:  2016-02-16       Impact factor: 4.458

4.  N-terminal pro-brain natriuretic peptide and cardiovascular or all-cause mortality in the general population: A meta-analysis.

Authors:  Zhaohua Geng; Lan Huang; Mingbao Song; Yaoming Song
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

5.  Biomarkers versus traditional risk factors to predict cardiovascular events in very old adults: cross-validated prospective cohort study.

Authors:  Bert Vaes; Paulien Indestege; Tinne Serneels; Eralda Hegendörfer; Petra G van Peet; Rosalinde K E Poortvliet; Pierre Wallemacq; Jacobijn Gussekloo; Jan Degryse
Journal:  BMJ Open       Date:  2020-06-28       Impact factor: 2.692

6.  Differences According to Age in the Diagnostic Performance of Cardiac Biomarkers to Predict Frailty in Patients with Acute Heart Failure.

Authors:  Lara Aguilar-Iglesias; Ana Merino-Merino; Ester Sanchez-Corral; Maria-Jesus Garcia-Sanchez; Isabel Santos-Sanchez; Ruth Saez-Maleta; Jose-Angel Perez-Rivera
Journal:  Biomolecules       Date:  2022-02-02

7.  What to Expect from Cardiovascular Life at 85?

Authors:  Wouter Kok
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

8.  Prognostic Value of Plasma NT-proBNP levels in Hospitalized Patients Older than 80 Years of Age in a Hospital in Beijing, China.

Authors:  Qiwei Zhu; Peng Gao; Shihui Fu; Hao Wang; Yongyi Bai; Leiming Luo; Ping Ye
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

9.  Systemic Inflammation and Cardio-Renal Organ Damage Biomarkers in Middle Age Are Associated With Physical Capability Up to 9 Years Later.

Authors:  Diana Kuh; Rachel Cooper; Naveed Sattar; Paul Welsh; Rebecca Hardy; Yoav Ben-Shlomo
Journal:  Circulation       Date:  2019-04-23       Impact factor: 29.690

10.  Associations between inflammation, cardiovascular biomarkers and incident frailty: the British Regional Heart Study.

Authors:  Douglas G J McKechnie; A Olia Papacosta; Lucy T Lennon; Sheena E Ramsay; Peter H Whincup; S Goya Wannamethee
Journal:  Age Ageing       Date:  2021-11-10       Impact factor: 12.782

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.